Literature DB >> 28314837

Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Roi Tschernichovsky1, Annekathryn Goodman2,3.   

Abstract

OBJECTIVE: The objective of this study was to review the role of bilateral salpingo-oophorectomy in BRCA mutation (mBRCA) carriers and alternative interventions in risk reduction of ovarian cancer (OC).
MATERIALS AND METHODS: A systematic review using PubMed, MEDLINE, EMBASE, and the Cochrane library was conducted to identify studies of different strategies to prevent OC in mBRCA carriers, including bilateral salpingo-oophorectomy, prophylactic salpingectomy with delayed oophorectomy, intensive surveillance, and chemoprevention.
RESULTS: Risk-reducing bilateral salpingo-oophorectomy is an effective intervention, but its associated morbidity is substantial and seems to curtail uptake rates among the target population. Although there is much interest and a strong theoretical basis for salpingectomy with delayed oophorectomy, data on its clinical application are scarce with regard to screening, the use of an algorithmic protocol has recently shown favorable albeit indefinite results in average-risk postmenopausal women. Its incorporation into studies focused on high-risk women might help solidify a future role for screening as a bridge to surgery. The use of oral contraceptives for chemoprevention is well supported by epidemiologic studies. However, there is a lack of evidence for advocating any of the other agents proposed for this purpose, including nonsteroidal anti-inflammatory drugs, vitamin D, and retinoids.
CONCLUSION: Further studies are needed before salpingectomy with delayed oophorectomy or intensive surveillance can be offered as acceptable, less morbid alternatives to upfront oophorectomy for mBRCA carriers. The Oncologist 2017;22:450-459 IMPLICATIONS FOR PRACTICE: Risk-reducing bilateral salpingo-oophorectomy is currently the most effective method for reducing the risk of ovarian cancer in BRCA mutation (mBRCA) carriers. Unfortunately, it is associated with significant short- and long-term morbidity, stemming from reduced circulating estrogen. In recent years, much research has been devoted to evaluating less morbid alternatives, especially multimodal cancer screening and prophylactic salpingectomy with delayed oophorectomy. This review describes the present state of the art, with the aim of informing the counseling provided to mBRCA carriers on this complicated issue and encouraging additional research to facilitate the incorporation of such alternatives into routine practice. © AlphaMed Press 2017.

Entities:  

Keywords:  BRCA; Bilateral salpingo‐oophorectomy; Chemoprevention; Ovarian cancer; Salpingectomy with delayed oophorectomy; Screening

Mesh:

Substances:

Year:  2017        PMID: 28314837      PMCID: PMC5388383          DOI: 10.1634/theoncologist.2016-0444

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  103 in total

1.  Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer.

Authors:  Xiaojian Ni; Jingjing Ma; Yingchun Zhao; Ying Wang; Shui Wang
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.

Authors:  C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

3.  Ovarian cancer screening: UKCTOCS trial.

Authors:  Peter D Sasieni; Stephen W Duffy; Jack Cuzick
Journal:  Lancet       Date:  2016-06-25       Impact factor: 79.321

4.  Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.

Authors:  Eric Leblanc; Fabrice Narducci; Isabelle Farre; Jean-Philippe Peyrat; Sophie Taieb; Claude Adenis; Philippe Vennin
Journal:  Gynecol Oncol       Date:  2011-03-15       Impact factor: 5.482

Review 5.  Aspirin and cancer risk: a quantitative review to 2011.

Authors:  C Bosetti; V Rosato; S Gallus; J Cuzick; C La Vecchia
Journal:  Ann Oncol       Date:  2012-04-19       Impact factor: 32.976

Review 6.  Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.

Authors:  Amy Finch; Steven A Narod
Journal:  Maturitas       Date:  2011-09-04       Impact factor: 4.342

7.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Authors:  Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

8.  Effect of fenretinide on ovarian carcinoma occurrence.

Authors:  Giuseppe De Palo; Luigi Mariani; Tiziana Camerini; Ettore Marubini; Franca Formelli; Barbara Pasini; Andrea Decensi; Umberto Veronesi
Journal:  Gynecol Oncol       Date:  2002-07       Impact factor: 5.482

9.  No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.

Authors:  B B J Hermsen; R I Olivier; R H M Verheijen; M van Beurden; J A de Hullu; L F Massuger; C W Burger; C T Brekelmans; M J Mourits; G H de Bock; K N Gaarenstroom; H H van Boven; T M Mooij; M A Rookus
Journal:  Br J Cancer       Date:  2007-04-10       Impact factor: 7.640

Review 10.  Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers.

Authors:  Claudia Marchetti; Francesca De Felice; Innocenza Palaia; Giorgia Perniola; Angela Musella; Daniela Musio; Ludovico Muzii; Vincenzo Tombolini; Pierluigi Benedetti Panici
Journal:  BMC Womens Health       Date:  2014-12-12       Impact factor: 2.809

View more
  9 in total

Review 1.  Association between dietary intake and risk of ovarian cancer: a systematic review and meta-analysis.

Authors:  Alireza Khodavandi; Fahimeh Alizadeh; Ahmad Faizal Abdull Razis
Journal:  Eur J Nutr       Date:  2020-07-13       Impact factor: 5.614

2.  Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.

Authors:  Mary Kathleen Ladd; Beth N Peshkin; Leigha Senter; Shari Baldinger; Claudine Isaacs; Hannah Segal; Samantha Philip; Chloe Phillips; Kate Shane; Aimee Martin; Veronique Weinstein; Robert Pilarski; Joanne Jeter; Kevin Sweet; Bonnie Hatten; Elisabeth J Wurtmann; Shanda Phippen; Della Bro; Marc D Schwartz
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

Review 3.  Surgery for BRCA, TP53 and PALB2: a literature review.

Authors:  Chin-Vern Song; Soo-Hwang Teo; Nur Aishah Taib; Cheng-Har Yip
Journal:  Ecancermedicalscience       Date:  2018-08-29

4.  Ovarian Cancer Previvors: How to manage these patients?

Authors:  Jesus Paula Carvalho; Edmund Chada Baracat; Filomena Marino Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2019-07-22       Impact factor: 2.365

Review 5.  Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.

Authors:  Concetta Altamura; Maria Raffaella Greco; Maria Rosaria Carratù; Rosa Angela Cardone; Jean-François Desaphy
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 6.  Essentiality of Trace Elements in Pregnancy, Fertility, and Gynecologic Cancers-A State-of-the-Art Review.

Authors:  James Curtis Dring; Alicja Forma; Zuzanna Chilimoniuk; Maciej Dobosz; Grzegorz Teresiński; Grzegorz Buszewicz; Jolanta Flieger; Tomasz Cywka; Jacek Januszewski; Jacek Baj
Journal:  Nutrients       Date:  2021-12-31       Impact factor: 5.717

7.  Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.

Authors:  Terhi Aino-Sofia Pallonen; Salla Maria Matleena Lempiäinen; Titta Kristiina Joutsiniemi; Riitta Irmeli Aaltonen; Pia Erika Pohjola; Minna Kristiina Kankuri-Tammilehto
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

Review 8.  Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

Authors:  George U Eleje; Ahizechukwu C Eke; Ifeanyichukwu U Ezebialu; Joseph I Ikechebelu; Emmanuel O Ugwu; Onyinye O Okonkwo
Journal:  Cochrane Database Syst Rev       Date:  2018-08-24

9.  Associations of genetic susceptibility to 16 cancers with risk of breast cancer overall and by intrinsic subtypes.

Authors:  Jungyoon Choi; Guochong Jia; Wanqing Wen; Ran Tao; Jirong Long; Xiao-Ou Shu; Wei Zheng
Journal:  HGG Adv       Date:  2021-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.